Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Autoimmune hemolytic anemia)
6,912 results
  • IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. [Journal Article]
  • TATher Adv Neurol Disord 2018; 11:1756285617744484
  • Liu X, Treister R, … Oaklander AL
  • CONCLUSIONS: These results provide Class IV, real-world, proof-of-concept evidence suggesting that IVIg is safe and effective for rigorously selected SFPN patients with apparent autoimmune causality. They provide rationale for prospective trials, inform trial design and indirectly support the discovery of small-fiber-targeting autoimmune/inflammatory illnesses.
  • [Evans syndrome in infants]. [Journal Article]
  • BMBol Med Hosp Infant Mex 2017 Mar - Apr; 74(2):141-146
  • Flores-Montes OA, Escobar-Orduño MC, … Valle-Leal JG
  • CONCLUSIONS: For the management of children with thrombocytopenia, the pediatrician must analyze for other cell lineage disorders. In the cases that we report here, we found the presence of autoimmune hemolytic anemia and monocytosis. Therefore, infectious and immunological studies must be included. The first-line treatment of choice are steroids, and intravenous immunoglobulin can be considered if severe immune thrombocytopenia is associated, as observed in these cases.
New Search Next